news
Charles River Laboratories announces extended relationship with The Michael J. Fox Foundation
Extension includes new project to phenotype Parkinson’s disease models and the continuation of LRRK2 research.
List view / Grid view
In Vivo
webinar
Biomarker endpoints for Parkinson’s disease
26 April 2018 | By Charles River Laboratories
This webinar provides a comprehensive review of the validation data from established and novel animal models of Parkinson’s disease.
article
High throughput flow cytometry for multifactorial evaluation of novel therapeutic candidates using an innovative in vitro immunooncology screening platform
This recent webinar focused on the role of IntelliCyt’s iQue Screener PLUS platform as a high throughput suspension cell screening platform to facilitate simultaneous assessment of multiple parameters, while using minimal sample volumes.
article
Expert view: Toward physiological relevance in drug discovery and development
Physiologically relevant screening models have become increasingly important in assay development and the screening of drug candidates.
article
Streamlining drug discovery assays for cancer and cardiovascular disease
Declining R&D productivity is a key challenge in the pharmaceutical industry. To increase the success rate of candidate drugs entering the clinical phase, companies must address the early stages of drug discovery.
news
Pro72Arg gene variant increases tumour cell metabolism
Scientists have found a mechanism through which mutant p53 enhances metastasis by controlling tumour metabolism...
news
Charles River Laboratories announces new tumour model compendium
The Compendium provides scientists an online resource to help design efficient in vitro and in vivo oncology research studies.
news
Researchers develop synthetic bioluminescence to view body’s cells externally
Researchers in Japan have ramped up nature’s wonder that is bioluminescence to enable deep tissue cells to be seen from outside the body.
news
Effective drug transfer tests look promising for placenta-on-a-chip technology
Researchers in America have demonstrated the feasibility of their ‘placenta-on-a-chip’ platform in studying how drugs are transported across the human placental barrier.
webinar
Streamlining drug discovery assays for cancer and cardiovascular disease
1 February 2018 | By PerkinElmer
This webinar discussed a screening assay that recapitulates the activation of ER stress sensor IRE1 and an assay to quantify cell migration phenotypes, as applied to cardiovascular target validation and drug discovery.
news
New radiotracer differentiates bacterial infection from inflammation in lungs
Researchers at the University of Louisville, Kentucky, have demonstrated that a new radiotracer, 2-18F-fluorodeoxysorbitol (18F-FDS), can identify and track bacterial infection in lungs better than current imaging methods and is able to differentiate bacterial infection from inflammation.
article
Identification of hits and leads for human African trypanosomiasis
Neglected tropical diseases (NTD) affect more than one billion people and new targets and drugs are needed to tackle these infections. The multi-disciplinary NMTrypI consortium has identified a number of different compound classes which could be effective against these diseases. This article reviews some of these compounds...
news
Charles River adds ERS License to CRISPR/Cas9 service offering
Charles River Laboratories International, Inc. announced the expansion of its CRISPR/Cas9 service offering with the addition of a license from ERS Genomics Limited.
news
Charles River Laboratories presents newly expanded capabilities at Neuroscience 2017
Charles River Laboratories International, Inc. announced that its team of neuroscience drug discovery experts is presenting 27 scientific posters, both independently and collaboratively with clients, at Neuroscience 2017, the 47th annual meeting of the Society for Neuroscience (SfN).
news
Charles River announces expansion of in vitro oncology services
Partnership with InSphero provides additional 3D solutions...
